CARsgen Therapeutics Holdings Ltd. has announced preliminary clinical data for its allogeneic BCMA-targeted CAR-T therapy, CT0596, developed using the THANK-u Plus™ platform. The therapy is currently being evaluated in investigator-initiated trials for the treatment of primary plasma cell leukemia (pPCL), a rare and aggressive plasma cell malignancy with limited treatment options. As of October 17, 2025, two patients with relapsed or refractory pPCL had been enrolled. Both patients achieved stringent complete response following CT0596 infusion, with robust CAR-T cell expansion and manageable safety profiles. Adverse events included cytokine release syndrome and hematologic toxicities, but no significant organ toxicities were observed. These results have already been presented and support continued investigation of CT0596 in plasma cell neoplasms.